Skip to content

Kudzu Treatment for Alcohol Abuse

Isoflavone (Kudzu) Extract Effects on Alcohol Drinking: Single Dose Pretreatment Study

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01596231
Acronym
KUDZU
Enrollment
20
Registered
2012-05-10
Start date
2010-05-31
Completion date
2014-07-31
Last updated
2014-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol Consumption

Keywords

Alcohol consumption, Kudzu extract

Brief summary

This is a study designed to test whether a single administration of kudzu extract (2 mg) will significantly reduce the number of drinks consumed during a single 1 ½ hours drinking session when given as pretreatment 2 ½ hours before the drinking session.

Detailed description

In a laboratory experimental setting, subjects will be treated with placebo or 2 grams of kudzu extract 2.5 hours before an afternoon drinking session. The investigators hypothesis is that the kudzu pretreatment will reduce alcohol consumption in this free choice, self-administration paradigm.

Interventions

DIETARY_SUPPLEMENTKudzu

Kudzu (2 mg) will be administered as a pretreatment 2 ½ hours before a drinking session to see if it will significantly reduce the number of drinks consumed during a single 1 ½ hours drinking session.

DIETARY_SUPPLEMENTPlacebo

Placebo will be administered as a pretreatment 2 ½ hours before a drinking session

Sponsors

National Institute on Alcohol Abuse and Alcoholism (NIAAA)
CollaboratorNIH
Mclean Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
21 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Capable of understanding and complying with the protocol * Good physical and mental health (normal physical exam, ECG, blood and urine chemistries) * Body Mass Index between 18-30, inclusive * Age 21-40 years * Moderate to heavy alcohol drinkers (on the average 20+ drinks/week) or a self-reported pattern of incidences of binge drinking 2 or more times per week (4 or more alcoholic beverages in one sitting) * Have a stable living situation with current postal address

Exclusion criteria

* Concurrent diagnosis of Axis I disorder * Current or past alcohol dependence; may meet criteria for alcohol abuse. Other drug dependence acceptable only if greater than 3 years. * Immediate family history pattern of alcoholism or problem drinking (parents or siblings) * Current drug abuse (other than alcohol or marijuana abuse). Past drug abuse is acceptable. * Subjects cannot be actively seeking treatment for any drug or alcohol dependence. * Subjects cannot use marijuana more than once a week. Marijuana abuse/dependence are acceptable if the use criteria is met. * Maintained on an antipsychotic or antidepressant medication; taking prescription medications except certain short-term anti fungal agents and some tropical creams for dermal conditions. * Tobacco use greater than 5 cigarettes per day * History of major head trauma resulting in cognitive impairment or history of seizure disorder * Heavy caffeine use (greater than 500 mg on a regular, daily basis) * Subject has active hepatitis and/or aspartate aminotransferase (AST), alanine aminotransferase (ALT) \> 3x the upper limit of normal * For female volunteers, a positive pregnancy test

Design outcomes

Primary

MeasureTime frameDescription
Drinking BehaviorsStudy endA variety of measures describing the drinking behavior will be analyzed with appropriate parametric tests (t-test, analysis of variance): number of beers consumed, weight and volume consumed, sip analysis (number, interlude), and latency (time to open first and subsequent drinks).

Countries

United States

Participant flow

Participants by arm

ArmCount
Placebo
This is a study designed to test whether a single administration of kudzu extract (2 mg) or placebo will significantly reduce the number of drinks consumed during a single 1 ½ hours drinking session when given as a pretreatment 2 ½ hours before the drinking session. Placebo: Placebo will be administered as a pretreatment 2 ½ hours before a drinking session
10
Kudzu
Kudzu 2mg Kudzu: Kudzu (2 mg) will be administered as a pretreatment 2 ½ hours before a drinking session to see if it will significantly reduce the number of drinks consumed during a single 1 ½ hours drinking session.
10
Total20

Baseline characteristics

CharacteristicTotalPlaceboKudzu
Age, Continuous23.6 years
STANDARD_DEVIATION 6.2
24.6 years
STANDARD_DEVIATION 3.3
22.6 years
STANDARD_DEVIATION 3.7
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants1 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
19 Participants9 Participants10 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
2 Participants1 Participants1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
18 Participants9 Participants9 Participants
Region of Enrollment
United States
20 participants10 participants10 participants
Sex: Female, Male
Female
0 Participants0 Participants0 Participants
Sex: Female, Male
Male
20 Participants10 Participants10 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 100 / 10
serious
Total, serious adverse events
0 / 100 / 10

Outcome results

Primary

Drinking Behaviors

A variety of measures describing the drinking behavior will be analyzed with appropriate parametric tests (t-test, analysis of variance): number of beers consumed, weight and volume consumed, sip analysis (number, interlude), and latency (time to open first and subsequent drinks).

Time frame: Study end

ArmMeasureValue (MEAN)Dispersion
PlaceboDrinking Behaviors3.4 beers consumedStandard Deviation 1.1
KudzuDrinking Behaviors1.9 beers consumedStandard Deviation 1.3

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026